免疫介导炎症性疾病患者使用生物制剂和小分子药物发生主要不良心血管事件的风险:网络荟萃分析
该系统检索截至2022年5月31日,纳入40项研究(36项随机对照试验和4项队列研究)、126,961例免疫介导炎症性疾病患者。网络荟萃分析显示,与安慰剂相比,抗TNF-α(OR 2.49;95%CrI 1.14-5.62)、JAK抑制剂(OR 2.64;95%CrI 1.26-5.99)和抗IL-12/23(OR 3.15;95%CrI 1.01-13.35)与主要不良心血管事件风险升高相关,不同类别或疾病类型间风险幅度无显著差异。
要点
- 与安慰剂相比,抗TNF-α、JAK抑制剂和抗IL-12/23与主要不良心血管事件风险升高相关。
- 不同药物类别之间或不同免疫介导炎症性疾病类型之间,主要不良心血管事件风险幅度无显著差异。
- 上述结果需在更大规模的前瞻性研究中确认。
核心结论
- 抗IL-12/23、JAK抑制剂和抗TNF-α与安慰剂相比与主要不良心血管事件风险升高相关。
- 主要不良心血管事件风险升高的幅度不因免疫介导炎症性疾病类型而异。
- 上述结果需在更大规模的前瞻性研究中确认。
研究设计与样本
- 系统检索PubMed、Embase、Ovid Medline、Scopus、Cochrane Central和ClinicalTrials.gov,检索时间从建库至2022年5月31日。
- 纳入评估≥18岁免疫介导炎症性疾病患者接受抗IL-23抗体、抗IL-12/23、抗TNF-α抗体或JAK抑制剂治疗时预设主要不良心血管事件风险的研究。
- 共纳入40项研究(36项随机对照试验和4项队列研究),包含126,961例免疫介导炎症性疾病患者。
- 采用随机效应模型进行网络荟萃分析,按药物类别和疾病状态报告汇总比值比(OR)及95%可信区间(CrI)。
主要发现
- 在3528项识别出的研究中,40项纳入系统评价,共126,961例免疫介导炎症性疾病患者。
- 基于随机对照试验的网络荟萃分析,无论疾病状态如何,抗TNF-α(OR 2.49;95%CrI 1.14-5.62)与安慰剂相比与主要不良心血管事件风险升高相关。
- JAK抑制剂(OR 2.64;95%CrI 1.26-5.99)与安慰剂相比与主要不良心血管事件风险升高相关。
- 抗IL-12/23(OR 3.15;95%CrI 1.01-13.35)与安慰剂相比与主要不良心血管事件风险升高相关。
- 不同药物类别之间或基于免疫介导炎症性疾病类型的主要不良心血管事件风险幅度无显著差异。
关键数值与推荐
- 预设主要不良心血管事件包括心肌梗死、脑血管意外、不稳定型心绞痛、心血管死亡或心力衰竭。
- 抗TNF-α与安慰剂相比:OR 2.49(95%CrI 1.14-5.62)。
- JAK抑制剂与安慰剂相比:OR 2.64(95%CrI 1.26-5.99)。
- 抗IL-12/23与安慰剂相比:OR 3.15(95%CrI 1.01-13.35)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出上述结果需在更大规模的前瞻性研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Recent studies raise concern for increased risk of major adverse cardiovascular events (MACE) with Janus kinase (JAK) inhibitors used to treat immune-mediated inflammatory disorders (IMIDs). We aimed to examine MACE risk with licensed biologics and small molecules used commonly between IMIDs: inflammatory bowel disease, rheumatoid arthritis, psoriasis/psoriatic arthritis, and ankylosing spondylitis. METHODS: Data were obtained from systematic searches (from inception to May 31, 2022) in PubMed, Embase, Ovid Medline, Scopus, Cochrane Central, and ClinicalTrials.gov. Studies that assessed a predefined MACE (myocardial infarction, cerebrovascular accident, unstable angina, cardiovascular death, or heart failure) risk in those ≥18 years of age with IMIDs treated with anti-interleukin (IL)-23 antibodies, anti-IL-12/23, anti-tumor necrosis factor α antibodies (anti-TNF-α), or JAK inhibitors were included in a network meta-analysis using a random-effects model with pooled odds ratios (ORs) reported with 95% credible intervals (CrIs) by drug class and disease state. RESULTS: Among 3528 studies identified, 40 (36 randomized controlled trials and 4 cohort studies) were included in the systematic review, comprising 126,961 patients with IMIDs. Based on network meta-analysis of randomized controlled trials, regardless of disease state, anti-TNF-α (OR, 2.49; 95% CrI, 1.14-5.62), JAK inhibitors (OR, 2.64; 95% CrI, 1.26-5.99), and anti-IL-12/23 (OR, 3.15; 95% CrI, 1.01-13.35) were associated with increased MACE risk compared with placebo. There was no significant difference in the magnitude of the MACE risk between classes or based on IMID type. CONCLUSIONS: Anti-IL-12/23, JAK inhibitors, and anti-TNF-α were associated with higher risk of MACE compared with placebo. The magnitude of the increased MACE risk was not different by IMID type. These results require confirmation in larger prospective studies.
引用
- Mattay SS, Zamani M, Saturno D, et al. Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis. Clin Gastroenterol Hepatol. 2023. PMID: 37821035. doi:10.1016/j.cgh.2023.09.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。